Results 121 to 130 of about 6,519 (211)
ABSTRACT Follicular lymphoma (FL) remains an incurable B‐cell malignancy with high relapse rates, and conventional therapies are often limited by significant toxicity, highlighting the need for novel treatments. We identified that FL exhibits markedly low expression of NAD(P)H: quinone oxidoreductase 1 (NQO1), a key enzyme required for activating ...
Jinxing Zhang +10 more
wiley +1 more source
In renal calcium oxalate stone formation, G6PC downregulation leads to lactate accumulation. This lactate mediates CBP/p300‐dependent lactylation of SNAIL1 at K206, promoting its nuclear translocation. Nuclear SNAIL1 activates the TGF‐β/SMAD3 pathway, driving epithelial‐mesenchymal transition and fibrosis, which ultimately facilitates crystal ...
Kai Liu +16 more
wiley +1 more source
Brown adipocyte sheets are engineered to protect the heart against myocardial ischemia–reperfusion injury by restraining ferroptosis. Upon transplantation onto the cardiac surface, they improve cardiac function, limit infarction and fibrosis, and enhance angiogenesis.
Lifu Sun +6 more
wiley +1 more source
A multifunctional β‐GP@EGCG‐E7 nanoplatform is engineered by polyphenol–peptide condensation and phosphate loading. Bone‐targeted delivery, antioxidant and anti‐inflammatory activity, and mitophagy restoration are integrated in one system, enabling protection of osteoblasts and endothelial cells and promoting bone regeneration under diabetic ...
Xiuyun Xu +13 more
wiley +1 more source
Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia +7 more
wiley +1 more source
Dual targeting of ANGPTL3 and IL‐33/ST2 attenuates diabetic kidney disease by reprogramming lipid–inflammatory crosstalk. This strategy reduces renal lipotoxicity, suppresses inflammatory activation, and limits fibrotic remodeling, thereby preserving kidney structure and function and highlighting a mechanism‐guided therapeutic approach for metabolic ...
Zhuojin Li +8 more
wiley +1 more source
HLP‐SeNPs, a Lysimachia christinae polysaccharide‐modified selenium nanoparticle, treat kidney stones by downregulating TOMM22 expression, which reduces PINK1 translocation into mitochondria and promotes its retention on the outer mitochondrial membrane.
Junyi Yang +10 more
wiley +1 more source
Renal IGFBP6 Interacts With THBS1 to Drive Renal Cellular Senescence and Fibrosis
ABSTRACT Epithelial dedifferentiation and myofibroblast activation are critical drivers of chronic kidney disease (CKD) progression. Elevated levels of IGFBP6 have been linked to decreased renal function in CKD patients, but its precise role and underlying mechanisms remain unclear.
Ju‐tao Yu +26 more
wiley +1 more source
The biomimetic self‐assembly nanomedicine reversing atherosclerosis via senotherapy strategy. ABSTRACT The greatest challenge in atherosclerosis (AS) management lies in achieving lesion reversal, not merely slowing progression. Senescent cell accumulation—driven by continuous generation and apoptotic resistance—perpetuates plaque pathology and ...
Yuhan Tian +9 more
wiley +1 more source
SuFEx‐Enabled Reprogramming of Flavonoids for Selective α‐Glucosidase Covalent Inhibition
Selective inhibition of intestinal α‐glucosidase remains limited by poor enzyme specificity and off‐target metabolic effects. Here, SuFEx click chemistry is used to reprogram natural flavonoids into covalent inhibitors with enhanced α‐glucosidase selectivity and controlled reactivity. This strategy enables effective regulation of carbohydrate digestion
Fengyu Guo +14 more
wiley +1 more source

